ES2135046T3 - 2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos. - Google Patents

2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos.

Info

Publication number
ES2135046T3
ES2135046T3 ES95912197T ES95912197T ES2135046T3 ES 2135046 T3 ES2135046 T3 ES 2135046T3 ES 95912197 T ES95912197 T ES 95912197T ES 95912197 T ES95912197 T ES 95912197T ES 2135046 T3 ES2135046 T3 ES 2135046T3
Authority
ES
Spain
Prior art keywords
pct
formula
trisustituted
disstituted
isoxazolines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95912197T
Other languages
English (en)
Inventor
Wilfried Schwab
Hiristo Anagnostopulos
Robert Ryder Bartlett
Rudolf Schleyerbach
Klaus Ulrich Weithmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2135046T3 publication Critical patent/ES2135046T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/50Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C205/51Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN COMPUESTO DE FORMULA (I) Y/O UNA SAL FISIOLOGICAMENTE ACEPTABLE DEL COMPUESTO DE FORMULA (I) Y/O UNA FORMA ESTEREOISOMERICA DEL COMPUESTO DE FORMULA (I), EN DONDE UN RADICAL R{SUP,1} O R{SUP,2} TIENE EL SIGNIFICADO DE FORMULA (II), ESTA INDICADO PARA LA OBTENCION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFLAMACIONES, ASMA, ENFERMEDADES REUMATICAS Y ENFERMEDADES AUTOINMUNES.
ES95912197T 1994-03-10 1995-03-03 2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos. Expired - Lifetime ES2135046T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4408084A DE4408084A1 (de) 1994-03-10 1994-03-10 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
ES2135046T3 true ES2135046T3 (es) 1999-10-16

Family

ID=6512412

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95912197T Expired - Lifetime ES2135046T3 (es) 1994-03-10 1995-03-03 2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos.

Country Status (17)

Country Link
US (1) US5814627A (es)
EP (1) EP0749429B1 (es)
JP (1) JPH09509951A (es)
KR (1) KR100330798B1 (es)
CN (1) CN1056836C (es)
AT (1) ATE181733T1 (es)
AU (1) AU684914B2 (es)
CA (1) CA2185004A1 (es)
DE (2) DE4408084A1 (es)
DK (1) DK0749429T3 (es)
ES (1) ES2135046T3 (es)
FI (1) FI963508A0 (es)
GR (1) GR3031266T3 (es)
HU (1) HU225499B1 (es)
NO (1) NO306723B1 (es)
TW (1) TW419469B (es)
WO (1) WO1995024397A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510361A (en) * 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents
AR029304A1 (es) * 1998-06-26 2003-06-25 Daiichi Seiyaku Co DERIVADOS DE PROPIONILO SUSTITUIDOS, PRODUCTO FARMACEUTICO, USO PARA LA FABRICACION DE UNA COMPOSICION FARMACEUTICA PARA LA PREVENCION Y/O TRATAMIENTO DE HIPERCOLESTEROLEMIA, HIPERLIPEMIA O ARTERIOESCLEROSIS, COMPOSICIoN FARMACÉUTICA Y COMPUESTOS INTERMEDIARIOS
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
EP1102755B1 (en) * 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
WO2000021959A1 (en) * 1998-10-09 2000-04-20 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
US6579880B2 (en) 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
EP1340749A4 (en) * 2000-11-17 2007-09-05 Takeda Pharmaceutical isoxazole
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
CA2494164A1 (en) * 2002-08-23 2004-03-04 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
US7326790B2 (en) * 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7220745B2 (en) * 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
WO2005034952A2 (en) * 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
SI1731512T1 (sl) 2004-03-05 2015-01-30 Nissan Chemical Industries, Ltd. Z izoksazolinom substituirana benzamidna spojina in sredstvo za uravnavanje škodljivih organizmov
US20050239751A1 (en) * 2004-03-26 2005-10-27 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
WO2007027230A2 (en) * 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
US9375009B2 (en) * 2011-12-27 2016-06-28 Bayer Intellectual Property Gmbh Heteroarylpiperidine and piperazine derivatives as fungicides
BR122015019867A2 (pt) 2013-01-14 2019-08-27 Kraton Polymers Us Llc processo para preparar um copolímero de bloco funcionalizado em amino
US20240336608A1 (en) * 2023-03-29 2024-10-10 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58148858A (ja) * 1982-02-26 1983-09-05 Yamanouchi Pharmaceut Co Ltd 3,5−ジ−tert−ブチル−4−ヒドロキシフエニル置換複素環化合物
IE59813B1 (en) * 1986-05-09 1994-04-06 Warner Lambert Co Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
US5086064A (en) * 1990-03-27 1992-02-04 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl thiazolyl, oxazolyl, and imidazolyl methanones and related compounds as antiinflammatory agents
US5510361A (en) * 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents

Also Published As

Publication number Publication date
CN1143956A (zh) 1997-02-26
EP0749429B1 (de) 1999-06-30
HU9602458D0 (en) 1996-11-28
HU225499B1 (en) 2007-01-29
DE59506310D1 (de) 1999-08-05
ATE181733T1 (de) 1999-07-15
DK0749429T3 (da) 2000-01-10
HUT76481A (en) 1997-09-29
KR970701703A (ko) 1997-04-12
AU1948195A (en) 1995-09-25
NO306723B1 (no) 1999-12-13
NO963560L (no) 1996-08-26
JPH09509951A (ja) 1997-10-07
CN1056836C (zh) 2000-09-27
KR100330798B1 (ko) 2002-10-11
WO1995024397A1 (de) 1995-09-14
FI963508A (fi) 1996-09-06
AU684914B2 (en) 1998-01-08
DE4408084A1 (de) 1995-09-14
FI963508A0 (fi) 1996-09-06
EP0749429A1 (de) 1996-12-27
TW419469B (en) 2001-01-21
CA2185004A1 (en) 1995-09-14
GR3031266T3 (en) 1999-12-31
US5814627A (en) 1998-09-29

Similar Documents

Publication Publication Date Title
ES2135046T3 (es) 2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos.
FI952607A (fi) Farmakologisesti aktiiviset pyridiinijohdannaiset ja menetelmät niiden valmistamiseksi
NO306346B1 (no) N-substituerte azabicykloalkanderivater, anvendelse derav og farmasöytisk preparat
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
PA8432901A1 (es) Compuestos de piridilpirrol
ES2166823T3 (es) Nuevos derivados pirrolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE69532580D1 (de) Neue antagonistische verbindungen
CO4290417A1 (es) Nuevas benzoilguanidinas como medicamentos y su preparacion .
EE03262B1 (et) Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
PT1124841E (pt) Fenil-alcenoil-guanidinas processo para a sua preparacao sua utilizacao como medicamentos ou meios de diagnostico bem como composicao farmaceutica que as contem
NO306400B1 (no) N-substituerte azabicykloheptan-derivater, anvendelse derav og farmasöytisk preparat
IL115184A0 (en) Anthracycline derivatives their preparation and use
FI92320C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
DK0675895T3 (da) Etoposidderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemiddel og anvendelse deraf til fremstilling af et lægemiddel til anticancerbehandling
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
ES2064948T3 (es) Polimetilen-iminas disustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
AU6519596A (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
IL107917A0 (en) Triazoloquinazolines, their preparation and their use as medicaments
HUP0103992A2 (hu) Pregnán-glükuronidok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 749429

Country of ref document: ES